Compare Cytokinetics Inc (CYTK) vs Centrus Energy Corp (LEU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Centrus Energy Corp — how do they compare? Cytokinetics Inc trades at $61.95 (market cap $8.62B), while Centrus Energy Corp trades at $144 (market cap $2.91B). The key difference: Cytokinetics Inc is far larger — about 3× Centrus Energy Corp's market cap, and Cytokinetics Inc is trading nearer its 52-week high, Centrus Energy Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Centrus Energy Corp for 29 Days on average.
| CYTK | LEU | |
|---|---|---|
Market Cap | $8.62B | $2.91B |
Volume | 2,594,626 | 903,777 |
Sector | Health | Energy |
52-Week High | $87.26 | $436.00 |
52-Week Low | $54.76 | $138.18 |
Typical Hold Time | 19 Days | 29 Days |
Enterprise Value | $8.72B | $2.22B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages despite some oversold RSI readings. The company reported a net loss of $784.96 million on $88.04 million revenue in 2025, with a negative net income margin of -1,321.12% in 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy and executive stock sales.
Wall Street maintains strong bullish sentiment with a 97.14% buy rating and $112.60 consensus price target, but high cash burn, persistent losses, and insider selling pose significant risks. The stock's outlook hinges on successful commercialization of its heart failure pipeline amid substantial financial and competitive pressures.
Centrus Energy (LEU) trades at $147.14, down 4.38% on the day, amid neutral technical signals and mixed earnings performance. The stock shows elevated valuation ratios with a P/E of 75.18 and P/S of 6.68, while profitability metrics include a 10.23% net income margin and 8.05% ROE. Recent news highlights Centrus' strategic positioning as a key supplier of High-Assay Low-Enriched Uranium (HALEU) for advanced nuclear reactors, supported by new multi-year supply contracts with Antares and Radiant announced in September 2026.
The investment case balances strong growth potential in the nuclear fuel market against execution risks and high valuation. Analyst consensus suggests 46% buy ratings with a $218.10 price target, implying significant upside, but investors face risks from cash flow volatility, competitive pressures, and the company's reliance on successful capacity expansion. The recent $500 million stock offering provides capital for growth but may dilute existing shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Centrus Energy Corp
Centrus Energy is a leading supplier of nuclear fuel and services for the global power industry. It specializes in supplying low-enriched uranium and developing next-generation fuels for advanced nuclear reactors.
Read more on LEU →
